National webinar on Bempedoic acid, a new oral lipid lowering treatment as add-on to improve LDL-C control in your (very) high risk CV patients.
Prof dr François Mach – What do the ESC/EAS guidelines about the management of dyslipidemias say?
Director of the cardiology basic science laboratory at the Faculty of Medicine University of Geneva, Switzerland
National CVD Prevention Coordinator for Switzerland
First author of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias
Prof dr Kausik Ray – How to use the clinical evidence of bempedoic acid in your daily clinical practice?
FESC, Professor of Public Health. Director of the Imperial Centre for CVD Prevention.
Deputy Director of Imperial Clinical Trials Unit and Head of Commercial Trials Imperial College London and Consultant Cardiologist. President European Atherosclerosis Society.